OccuLogix, a biotech startup founded near Toronto, Canada, in 1996 to develop ophthalmic treatments for age-related macular degeneration and glaucoma, apparently has relocated in San Diego, according to an SEC filing. In its Form D filed today, OccuLogix discloses that it has raised more than $1.7 million from investors in a round that intends to raise $5 million.
The company is listed as a Toronto-area company on LinkedIn and Hoover’s. But OccuLogix, which is now doing business as TearLab, lists a San Diego address in its SEC filing and on its website. The company describes itself as an “in-vitro diagnostics company developing and commercializing novel, lab-on-a-chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.”